ACP
CLDX icon

Acuta Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

Acuta Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500,000
Closed -$16.7M – 51
2021
Q2 		$16.7M Buy
+500,000
New +$13.7M 6.68% 3

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's CLDX Position: Q2 2024 in Review

Acuta Capital Partners sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 109,000 shares — an estimated $4.57M sold.

Acuta Capital Partners first reported a position in CLDX in Q2 2020 and held it in 16 quarters. The position peaked at $33M in Q2 2021. 182 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Acuta Capital Partners reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 109,000 Celldex Therapeutics shares in Q2 2024, an estimated $4.57M.
  • Acuta Capital Partners first reported a position in Celldex Therapeutics in Q2 2020 and held it in 16 quarters.
  • Acuta Capital Partners's Celldex Therapeutics position peaked at $33M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.